Tuning Extracellular Vesicle Production and Analytics for Compliance
A company developing extracellular vesicles (EV) derived from umbilical cord blood cells says that producing a non-conventional product shouldn’t be a barrier to streamlined production processes and quality control analytics.
Exogenus Therapeutics, which is currently developing products targeted at inflammatory and degenerative conditions, says that they’ve managed to implement a production and quality-control (QC) workflow that turns their complicated high-screening analytics into a more sustainable assay panel.
“I think our main message to the corporate EV community is it’s possible to develop and produce an extracellular vesicle-based product that falls outside the mainstream,” explains Andreia Silva, PhD, head of research at Exogenus, who spoke at Cell & Gene Therapy International Europe.
According to Silva, complexities of their production process include the raw material of umbilical cord blood, which has a higher level of variability than conventional EV cell sources as it’s derived from different donors, but which needs to be sculpted into a safe and consistent-quality product.
The product is also complex, she explains, as unlike small molecules, extracellular vesicles are made of thousands of molecules of lipids, proteins, metabolites, DNA, and RNA, all of which may be functional once they reach a target organ.
To overcome this complexity issue, as they move toward the clinical stage of development, the company says it’s managed to develop a production strategy including a panel of assays that can be run using standardized techniques, such as ELISA and Western Blot, to provide efficient and sustainable QC of product batches.
“We can’t do omics on every single batch of product we are going to release because it would become too expensive down the line,” explains Silva. “We’ve been looking at the molecular data generated at the omics level and then selecting specific targets to pass that into the simpler QC panel.”
Although their target choices and QC panel are product-specific, Silva hopes the general lessons will inspire other companies in their QC development. Going forward, she says a future challenge for the EV industry will be developing potency assays.
“Potency assay development for GMP production, so you can use your product in later clinical phases, is still something that needs a lot of development because EVs are such a complex modality,” she says.
“As companies work toward getting an EV product to clinic, we can definitely see strategies emerging for what might be the right way to go.”
The post Tuning Extracellular Vesicle Production and Analytics for Compliance appeared first on GEN - Genetic Engineering and Biotechnology News.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
